Hospitals groups were deeply disappointed last week with the U.S. Centers for Medicare & Medicaid Services’ (CMS) proposal to continue a nearly 30% cut in Medicare Part B reimbursement for hospitals’ 340B purchased drugs in place since 2018.
Another provision in CMS’ hospital outpatient prospective payment system (OPPS) proposed rule for 2022 might console them. CMS is recommending 24 drugs and three biosimilars have their “pass-through” status extended for up to a year—a move that would temporarily shield the medicines from the deep payment cut for 340B hospitals. It also could prompt more covered entities to turn to biosimilars.
Hospitals groups were deeply disappointed last week with the U.S. Centers for Medicare & Medicaid Services’ (CMS) proposal to continue a nearly 30% cut in Medicare Part B reimbursement for hospitals’ 340B purchased drugs in place since 2018.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.